Debevoise & Plimpton LLP has filed an amicus curiae brief in the U.S. District Court for the Northern District of Texas on behalf of twelve leading medical organizations in an effort to protect the use of mifepristone, a drug commonly used for medication abortions, as well as miscarriage care and other treatments. Plaintiffs in this case have filed a motion seeking to enjoin or limit the use of mifepristone after nearly twenty-three-years of FDA approval.

The brief underscores that the FDA’s approval of mifepristone more than two decades ago was based on a comprehensive and thorough review of the scientific evidence. The brief further highlights the consensus of the medical and scientific community that mifepristone has been and continues to be both safe and effective, and that the Plaintiffs’ purported concerns over the medication’s safety are unfounded. The brief also makes clear that restricting access to mifepristone will exacerbate the risks already associated with pregnancy and childbirth, and will inevitably impede access to quality care, particularly for marginalized communities.

The brief was filed on behalf of the American College of Obstetricians and Gynecologists, the American Medical Association, the Society for Maternal-Fetal Medicine, the American Academy of Family Physicians, the American Gynecological & Obstetrical Society, the American Society for Reproductive Medicine, the Council of University Chairs of Obstetrics & Gynecology, the North American Society for Pediatric and Adolescent Gynecology, Nurse Practitioners in Women's Health, the Society of Family Planning, the Society of Gynecologic Oncology, and the Society of OB/GYN Hospitalists.

The Debevoise team is led by litigation partner Shannon Rose Selden and associates Adam Aukland-Peck and Megan McGuiggan, and includes associates Leah Rosenberg, Hillary Hubley, and Anu Chugh, along with law clerks Prakriti Luthra and Charlotte Blatt.